UK-based Anglo-Swedish multinational pharmaceutical and biotechnology company, AztraZeneca Plc, announced on November 1, a deal with another company in the fast-growing CGT market.
AstraZeneca Pharma India has received import and market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100 mg capsules (Calquence ).